Request Demo
Last update 22 Feb 2025
Deoxypodophyllotoxin
Last update 22 Feb 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms DPT |
Target |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Login to view timeline
Structure/Sequence
Molecular FormulaC22H22O7 |
InChIKeyZGLXUQQMLLIKAN-SVIJTADQSA-N |
CAS Registry19186-35-7 |
Related
4
Clinical Trials associated with DeoxypodophyllotoxinCTR20180179
《注射用去氧鬼臼毒素在晚期实体瘤患者中的耐受性、药代动力学、剂量扩展的I期临床试验》
[Translation] Phase I clinical trial of tolerability, pharmacokinetics, and dose expansion of deoxypodophyllotoxin for injection in patients with advanced solid tumors
CTRI/2018/04/013478
STUDY OF REDUCING PAIN BY TOPICAL ANAESTHETIC IN INFANTS DURING DPT COMBO VACCINATION: RANDOMIZED CONTROL TRIAL
ISRCTN84560580
Information and the demand for preventative healthcare: a randomised controlled trial of improving household perceptions on the efficacy of DPT immunisation in Uttar Pradesh, India
100 Clinical Results associated with Deoxypodophyllotoxin
Login to view more data
100 Translational Medicine associated with Deoxypodophyllotoxin
Login to view more data
100 Patents (Medical) associated with Deoxypodophyllotoxin
Login to view more data
1,216
Literatures (Medical) associated with Deoxypodophyllotoxin01 Mar 2025Journal, physical therapy education
Web Site Accessibility Among Doctor of Physical Therapy Programs in the United States
Article
Author: Parent-Nichols, Jennifer ; Wilhelm, Mark P ; Ness, Brandon M ; Pathare, Neeti ; Wonsetler-Jones, Elizabeth C
Introduction.:
Given the impetus to improve accessibility for diverse learners seeking physical therapist education, it is critical that all entry points to access information have minimal barriers. This study identified Web site accessibility barriers among Doctor of Physical Therapy (DPT) programs in the United States.
Review of Literature.:
Web site accessibility has been evaluated among many institutions of higher education, but none focused on DPT education. Individuals with disabilities may be adversely affected by Web site accessibility barriers.
Subjects.:
This cross-sectional study included 262 DPT programs in the United States. Doctor of Physical Therapy program characteristics collected were geographic region, institutional control type (public/private), medical school affiliation, accreditation status, total institutional enrollment, and DPT class size.
Methods.:
The Web Accessibility Evaluation (WAVE) Tool assessed data related to accessibility barriers among DPT program homepage Uniform Resource Locators. Three primary outcomes from the WAVE Tool included WAVE Total Errors, Error Density, and Total Alerts.
Results.:
Web site homepage accessibility barriers varied among programs for WAVE Total Errors (range 0–150), Error Density (range 0–14.6%), and Total Alerts (range 1–331). Median Total Errors were greater among private (9.0) versus public (5.0) institution Web sites (P < .001). Median Total Errors were greater among those institutions not affiliated with a medical school (9.0) compared with those that had an affiliated medical school (7.0) (P = .04). No differences in accessibility barriers were identified according to geographic region or accreditation status (P > .05). Median Total Errors were significantly different between institutional enrollment quartiles (H[3] = 17.9, P < .001), with no differences noted between DPT class size quartiles for any outcome (P > .05). Generally, weak–fair inverse correlations were observed between student enrollment for the institution and Web site accessibility barrier outcomes.
Discussion and Conclusion.:
Homepage accessibility barriers varied greatly among DPT programs in the United States. Factors, including being a private institution, no medical school affiliation, and lower institutional enrollment, were related to increased accessibility barriers.
01 Jan 2025PHYTOCHEMISTRY
Targeted isolation of lignans from the roots of Anthriscus sylvestris (L.) Hoffm. by small molecule accurate recognition technology
Article
Author: Zheng, Ya-juan ; Cao, Yan-Gang ; Cao, Yan-gang ; Liu, Yan-ling ; Li, Xiang-da ; Ma, Xin-Yi ; Ma, Xin-yi ; Zheng, Xiao-ke ; Feng, Wei-sheng ; Zheng, Ya-Juan ; Zheng, Xiao-Ke ; Chen, Lan ; Niu, Ying ; Chen, Xu ; Feng, Wei-Sheng ; Liu, Yan-Ling
Five undescribed lignans (1-5), along with sixteen known lignans (6-21), were isolated from the roots of Anthriscus sylvestris using small molecule accurate recognition technology (SMART). The structures of the isolated compounds were determined by comprehensive spectroscopic analyses, and the absolute configurations of compounds 3-5 were elucidated by comparison of their calculated and experimental ECD spectra. Compounds 5, 14-15, 19, and 21 exhibited significantly inhibitory effects against hypoxia-stimulated abnormal proliferation of pulmonary arterial smooth muscle cells (PASMCs). Moreover, compounds 5, 14-15, 19, and 21 can significantly restore expression of expression of PASMCs proliferation-related protein, including α-SMA, PCNA, P27, and CyclinD3, which are closely related to cell proliferation.
01 Jan 2025JOURNAL OF ETHNOPHARMACOLOGY
Assessing the potential fasting and postprandial mechanisms involved in the acute hypoglycemic and anti-hyperglycemic effects of four selected plants from Iran used in traditional Persian medicine
Article
Author: Andrade-Cetto, Adolfo ; Escandón-Rivera, Sonia M ; Espinoza-Hernández, Fernanda A ; Safavi, Fereshteh
ETHNOPHARMACOLOGICAL RELEVANCE:
In traditional Persian medicine (TPM), people often use herbal infusions as a dosage form to treat diseases related to hyperglycemia, known as 'dam-kardeh'. Traditionally, herbal preparations of Eryngium bungei Boiss. (E. b), Tragopogon buphthalmoides (DC.) Boiss. (T. b), Salvia hydrangea DC. ex Benth. (S. h), and Juniperus polycarpos K. Koch. (J. p) are used to manage diabetes in Iran. However, there is no evidence of their effectiveness in controlling glucose levels and their mechanisms remain unclear.
AIM OF THE STUDY:
This study aimed to investigate whether traditional doses of plant infusions can have hypoglycemic and/or anti-hyperglycemic effects during fasting and/or postprandial states and establish the basis for future research on their potential mechanisms of action.
MATERIALS AND METHODS:
The effects of traditional doses of herbal extracts on blood glucose levels in STZ-NA-induced hyperglycemic rats were investigated in 2-h acute tests during fasting and postprandial states (with a glucose load). In addition, the potential inhibitory effect in vitro of enzymes involved in relevant pathways, such as gluconeogenesis (fructose-1,6-bisphosphatase, FBPase and glucose-6-phosphatase, G6Pase), carbohydrate breakdown (intestinal α-glucosidases), and insulin sensitivity (protein tyrosine phosphatase 1B, PTP-1B) was evaluated. Acute toxicity tests were carried out and HPLC-SQ-TOF was used to analyze the chemical profiles of the plant extracts.
RESULTS:
In the fasting state, T. b, S. h, and E. b were as effective as glibenclamide in lowering blood glucose levels in hyperglycemic rats. Moreover, all three suppressed G6Pase and FBPase enzymatic activity by 90-97% and 80-91%, respectively. On the other hand, significant postprandial hypoglycemic efficacy was observed for E. b, S. h, and T. b. Based on the AUC values, T. b caused a reduction comparable to the therapeutic efficacy of repaglinide. When investigating the possible mechanisms of action involved in this activity, E. b, S. h, and T. b showed significant inhibition of PTP-1B in vitro (>70%). Finally, all plant extracts showed no signs of acute toxicity. Several compounds that may contribute to biological activities were identified, including phenolic acids and flavonoid glycosides.
CONCLUSIONS:
The present study supports the traditional use of T. b, E. b and S. h for the control of diabetes in the fasting and postprandial state. Moreover, these plants were found to be rich in bioactive compounds with hypoglycemic and antihyperglycemic activities. On the other hand, J. p, showed a modest effect only in the fasting state and after 90 min. Further studies are needed to expand these results by analyzing the chemical composition and using complementary experimental models.
100 Deals associated with Deoxypodophyllotoxin
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 06 Jul 2018 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 06 Jul 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free